Pall Corporation Launches Web Site on Blood Transfusion

Publication
Article
OncologyONCOLOGY Vol 12 No 11
Volume 12
Issue 11

One in 20 Americans will require a blood transfusion at some point in their lives. Yet, many remain uninformed about the reason for transfusions, the risks associated with them, and ways to avoid or minimize them. Pall Corporation has launched a

One in 20 Americans will require a blood transfusion at some point in their lives. Yet, many remain uninformed about the reason for transfusions, the risks associated with them, and ways to avoid or minimize them. Pall Corporation has launched a web site--Blood Transfusions: Knowing Your Options--as an educational service to the public. The site can be accessed through the address: www.bloodtransfusion.com and includes information provided by America’s Blood Centers and the American Association of Blood Banks, as well as links to those and other health-related web sites. It describes the components of blood and explains how one of those components, leukocytes (white blood cells), can carry disease or weaken an immune system.

Filtering Leukocytes

It is important for the public to know, says Pall, that if they need a transfusion, they should demand blood that has been filtered to reduce leukocytes and the viruses associated with them. Visitors to http://www.b1oodtransfusion.com will find a card that they can print and carry in their wallets that specifies their wishes regarding any blood products needed in an emergency.

As public awareness of blood-transmitted diseases grows, patients need to understand what the risks, benefits, and their options are when a blood transfusion is called for. Recognizing that fact, industrialized nations are moving toward adopting routine leukocyte filtration as standard practice. Recently, the United Kingdom joined Austria, France, Ireland, Norway, and Portugal, in requiring that leukocyte reduction by prefiltration be implemented to protect public health and safety. The Canadian Red Cross also recently began the use of leukocyte reduction by filtration for all whole-blood-derived platelets. In the United States, where 12 million units of blood are collected annually, 60% to 70% of platelet components are leukocyte-reduced; 20% of red cells are leukocyte-reduced.

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content